SCHEDULE: Vanguard Group Discloses 5.13% Stake in Ginkgo Bioworks Holdings Inc.

The Vanguard Group has reported a 5.13% beneficial ownership stake in Ginkgo Bioworks Holdings Inc., primarily for investment purposes.

Summary

• The Vanguard Group, an investment adviser based in Pennsylvania, has filed a Schedule 13G indicating beneficial ownership in Ginkgo Bioworks Holdings Inc.
• As of June 30, 2025, The Vanguard Group beneficially owned an aggregate of 2,381,115 shares of Ginkgo Bioworks Holdings Inc. Common Stock.
• This ownership represents 5.13% of the total class of securities.
• The Vanguard Group holds sole voting power over 0 shares, shared voting power over 23,188 shares, sole dispositive power over 2,318,136 shares, and shared dispositive power over 62,979 shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the company's performance or outlook.

Future Outlook

NA

Industry Context

This filing reflects a routine disclosure by a major institutional asset manager, The Vanguard Group, regarding its passive investment holdings. Such disclosures are common for large fund managers who frequently cross beneficial ownership thresholds in publicly traded companies as part of their diversified investment strategies.

Stakeholder Impact

• Shareholders may view the disclosure of a significant stake by a major institutional investor like The Vanguard Group as a positive signal, potentially indicating institutional confidence in Ginkgo Bioworks Holdings Inc.

Key Dates

Keywords

Ginkgo Bioworks, Vanguard Group, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Institutional Investor, Biotechnology, Synthetic Biology